Supernus Pharmaceuticals Other Non-Current Liabilities 2011-2024 | SUPN
Supernus Pharmaceuticals other non-current liabilities from 2011 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Supernus Pharmaceuticals Annual Other Non-Current Liabilities
(Millions of US $) |
| 2023 |
$8 |
| 2022 |
$43 |
| 2021 |
$52 |
| 2020 |
$89 |
| 2019 |
$29 |
| 2018 |
$34 |
| 2017 |
$33 |
| 2016 |
$31 |
| 2015 |
$35 |
| 2014 |
$40 |
| 2013 |
$15 |
| 2012 |
$2 |
| 2011 |
$2 |
| 2010 |
$ |
Supernus Pharmaceuticals Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-09-30 |
$8 |
| 2024-06-30 |
$8 |
| 2024-03-31 |
$8 |
| 2023-12-31 |
$8 |
| 2023-09-30 |
$16 |
| 2023-06-30 |
$42 |
| 2023-03-31 |
$62 |
| 2022-12-31 |
$43 |
| 2022-09-30 |
$20 |
| 2022-06-30 |
$22 |
| 2022-03-31 |
$23 |
| 2021-12-31 |
$52 |
| 2021-09-30 |
$64 |
| 2021-06-30 |
$65 |
| 2021-03-31 |
$86 |
| 2020-12-31 |
$89 |
| 2020-09-30 |
$57 |
| 2020-06-30 |
$118 |
| 2020-03-31 |
$28 |
| 2019-12-31 |
$29 |
| 2019-09-30 |
$32 |
| 2019-06-30 |
$32 |
| 2019-03-31 |
$33 |
| 2018-12-31 |
$34 |
| 2018-09-30 |
$37 |
| 2018-06-30 |
$36 |
| 2018-03-31 |
$36 |
| 2017-12-31 |
$33 |
| 2017-09-30 |
$28 |
| 2017-06-30 |
$29 |
| 2017-03-31 |
$30 |
| 2016-12-31 |
$31 |
| 2016-09-30 |
$33 |
| 2016-06-30 |
$34 |
| 2016-03-31 |
$35 |
| 2015-12-31 |
$35 |
| 2015-09-30 |
$35 |
| 2015-06-30 |
$36 |
| 2015-03-31 |
$35 |
| 2014-12-31 |
$40 |
| 2014-09-30 |
$40 |
| 2014-06-30 |
$12 |
| 2014-03-31 |
$12 |
| 2013-12-31 |
$15 |
| 2013-09-30 |
$25 |
| 2013-06-30 |
$20 |
| 2013-03-31 |
$2 |
| 2012-12-31 |
$2 |
| 2012-09-30 |
$3 |
| 2012-06-30 |
$3 |
| 2012-03-31 |
$3 |
| 2011-12-31 |
$2 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
